Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation

  • Clin Transl Immunology. 2015 Mar 27;4(3):e35. doi: 10.1038/cti.2015.5.
Chien-Li Holmes-Liew  1 ,  Mark Holmes  1 ,  Leone Beagley  2 ,  Peter Hopkins  3 ,  Daniel Chambers  3 ,  Corey Smith  2 ,  Rajiv Khanna  2
Affiliations
  • 1. South Australian Lung Transplant Unit, Department of Thoracic Medicine, Royal Adelaide Hospital , Adelaide, South Australia, Australia ; Faculty of Health Sciences, School of Medicine, University of Adelaide , Adelaide, South Australia, Australia.
  • 2. QIMR Centre for Immunotherapy and Vaccine Development, QIMR Berghofer Medical Research Institute , Brisbane, Queensland, Australia.
  • 3. Queensland Lung Transplant Service, The Prince Charles Hospital , Brisbane, Queensland, Australia ; School of medicine, The University of Queensland , Brisbane, Queensland, Australia.
PMID: 25859390 DOI: 10.1038/cti.2015.5
Abstract

Infections with cytomegalovirus (CMV) can induce severe complications after solid organ transplantation (SOT). The prognosis for ganciclovir-resistant CMV Infection and disease is particularly poor. Whereas adoptive transfer of CMV-specific T cells has emerged as a powerful tool in hematopoietic stem cell transplant patients, its translation into the SOT setting remains a significant challenge as underlying immunosuppression inhibits the virus-specific T-cell response in vivo. Here, we demonstrate successful expansion and adoptive transfer of autologous CMV-specific T cells from a seronegative recipient of a seropositive lung allograft with ganciclovir-resistant CMV disease, resulting in the long-term reconstitution of protective anti-viral immunity, CMV Infection, disease-free survival and no allograft rejection.

Products